Entity Details

Primary name HCDH_HUMAN
Entity type UniProt
Source Source Link

Details

AccessionQ16836
EntryNameHCDH_HUMAN
FullNameHydroxyacyl-coenzyme A dehydrogenase, mitochondrial
TaxID9606
Evidenceevidence at protein level
Length314
SequenceStatuscomplete
DateCreated1997-11-01
DateModified2021-06-02

Ontological Relatives

GenesHADH

GO terms

Show/Hide Table
GOName
GO:0003857 3-hydroxyacyl-CoA dehydrogenase activity
GO:0005654 nucleoplasm
GO:0005737 cytoplasm
GO:0005739 mitochondrion
GO:0005759 mitochondrial matrix
GO:0006635 fatty acid beta-oxidation
GO:0016740 transferase activity
GO:0042802 identical protein binding
GO:0050796 regulation of insulin secretion
GO:0070403 NAD+ binding
GO:0120162 positive regulation of cold-induced thermogenesis

Subcellular Location

Show/Hide Table
Subcellular Location
Mitochondrion matrix

Domains

Show/Hide Table
DomainNameCategoryType
IPR006108 3-hydroxyacyl-CoA dehydrogenase, C-terminalDomainDomain
IPR006176 3-hydroxyacyl-CoA dehydrogenase, NAD bindingDomainDomain
IPR006180 3-hydroxyacyl-CoA dehydrogenase, conserved siteSiteConserved site
IPR008927 6-phosphogluconate dehydrogenase-like, C-terminal domain superfamilyFamilyHomologous superfamily
IPR013328 6-phosphogluconate dehydrogenase, domain 2FamilyHomologous superfamily
IPR022694 3-hydroxyacyl-CoA dehydrogenaseFamilyFamily
IPR036291 NAD(P)-binding domain superfamilyFamilyHomologous superfamily

Diseases

Show/Hide Table
Disease IDSourceNameDescription
231530 OMIM3-alpha-hydroxyacyl-CoA dehydrogenase deficiency (HADH deficiency)An autosomal recessive, metabolic disorder with various clinical presentations including hypoglycemia, hepatoencephalopathy, myopathy or cardiomyopathy, and in some cases sudden death. The disease is caused by variants affecting the gene represented in this entry.
609975 OMIMFamilial hyperinsulinemic hypoglycemia 4 (HHF4)Most common cause of persistent hypoglycemia in infancy. Unless early and aggressive intervention is undertaken, brain damage from recurrent episodes of hypoglycemia may occur. HHF4 should be easily recognizable by analysis of acylcarnitine species and that this disorder responds well to treatment with diazoxide. It provides the first 'experiment of nature' that links impaired fatty acid oxidation to hyperinsulinism and that provides support for the concept that a lipid signaling pathway is implicated in the control of insulin secretion. The disease is caused by variants affecting the gene represented in this entry.

Drugs

Show/Hide Table
DrugNameSourceType
DB00157 NADHDrugbanksmall molecule
DB03059 Acetoacetyl-CoADrugbanksmall molecule
DB03612 3-Hydroxybutyryl-Coenzyme ADrugbanksmall molecule
DB09568 Omega-3-carboxylic acidsDrugbanksmall molecule